Top Ten Common Prejudices About Polyethylene Naphthalate Market.
Global Urinary Incontinence Treatment Drugs Market, by Incontinence Type (Urge Incontinence, Stress Incontinence, Over-flow Incontinence, Mixed Incontinence, and Others), by Drug Class (Anticholinergic/Antispasmodic Agents, Skeletal Muscle Relaxants, Antidepressants, Alpha Blockers, Topical Estrogens, and Others), and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and (2020-2027)
The high incidence and increasing prevalence of urine incontinence around the world, as well as increased product approvals by regulatory bodies, are driving the global market for urinary incontinence treatment medications.
According to the World Health Organization's (WHO) Integrated Care for Older People (ICOPE) recommendations, a population-based study called "Evidence profile: urinary incontinence" was conducted in the United States and Nordic countries in 2017. (Denmark, Norway, Sweden). Urinary incontinence was shown to be more common in older women than in older men, with rates ranging from 9.9% to 36.1 percent.
For example, Urovant Sciences, Inc stated in March 2020 that its Vibegron for the Treatment of Patients with Overactive Bladder (OAB) with symptoms of urge urine incontinence, urgency, and urinary frequency has been accepted by the US Food and Drug Administration (FDA).
COVID-19's rapid proliferation is posing a challenge to healthcare systems around the world. In many nations, hospitals and ICU departments are overburdened or on the verge of collapsing due to a lack of healthcare resources essential for ICU treatments.
Since December 2019, a novel coronavirus has spread throughout China and the rest of the world, resulting in a rapid increase in confirmed cases. The disease has spread to over 200 nations throughout the world, prompting the WHO to declare it a public health emergency.
Comments
Post a Comment